FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

20 CSR 2220-2.025(1) bars nonresident pharmacies from shipping, mailing or delivering prescription drugs into Missouri without a Missouri pharmacy license. There are two exceptions: emergencies, and refills of a prescription first filled and delivered in the pharmacy's home state. The applicant needs a home-state pharmacy license in good standing. Its pharmacist in charge must hold either a Missouri license or an active license in the home state, with an official verification if not Missouri-licensed. If it ships controlled substances, it must file its DEA and state controlled-substance registrations. It must also file its most recent home-state inspection: within 18 months for sterile compounding applicants and 24 months for all others. If no state inspection is available, the Board may accept its own inspection, an NABP Verified Pharmacy Program (VPP) inspection, or one by another Board-approved entity. The permit lists each class of pharmacy practiced, such as Class D non-sterile compounding or Class H sterile compounding (20 CSR 2220-2.020(9)–(10)). RSMo §338.220 makes it unlawful to operate any pharmacy without a Board permit.

The rule was last amended effective 4/30/2018 and is still in force according to the Board's 2025 Practice Guide and current application list. The Board's forms page lists a 'Pharmacy Permit Application (Non-resident facility)'. The official Secretary of State CSR PDF blocked fetching, so the LII copy was used. Correction to the lead: 'Class R' is the Remote Dispensing Site Pharmacy permit (RSMo §338.215, §338.220(18)), not a nonresident credential. Change: the sterile compounding rule 20 CSR 2220-2.200 was revised effective 7/30/2026 to adopt USP <797> (2023), and it applies to all Class H sterile compounding permit holders.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

20 CSR 2220-2.400(12) provides that 'pharmacists shall not offer or provide compounded preparations to other pharmacies, practitioners, or entities for subsequent dispensing, distribution, resale, or administration,' except for a prescriber to give to an individual patient on a prescription the pharmacy dispensed. Rule 2.400(10) prohibits compounding without a prescription or medication order. The Board's 2025 Practice Guide says compounded preparations may not be offered to practitioners for office use. A pharmacy may, however, dispense a patient-specific compounded preparation for the prescriber to administer in the office. An FDA-registered 503B facility may supply office-use preparations if it is licensed as a Missouri drug outsourcer. The only non-patient-specific exceptions are veterinary office stock for Missouri-licensed veterinarians (2.400(13)) and a drug-shortage exception for Class B hospital pharmacies. This matches FDA's patient-specific view of 503A.

Rule 2.400 was last amended effective 9/30/2023. It also bars compounding essentially copies of commercially available products unless the prescriber documents a patient-specific medical need or clinically significant difference (2.400(9)). Pharmacists may use only drug substances made or distributed by Missouri-licensed or registered drug distributors (2.400(6)(B)). The Board revised its sterile compounding rule (20 CSR 2220-2.200) effective 7/30/2026 but did not revise rule 2.400. Stale-source flag: the controlling text is dated 2023-09-30 (more than 2 years before 2026-09-23); it is the latest version found, but confirm with the board that it is still current.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

RSMo §338.330(1) defines a 'drug outsourcer' as an outsourcing facility under 21 U.S.C. §353b. §338.333 bars acting as a drug outsourcer without a Board license. §338.337 makes it unlawful for an out-of-state drug outsourcer to do business in Missouri without a license. §338.340 bars anyone acting for an out-of-state drug outsourcer from selling or distributing drugs in Missouri unless the outsourcer is licensed. The Board's Drug Outsourcer Application (resident and nonresident) requires: FDA 503B registration; the most recent FDA 503B inspection report, if available; a home-state outsourcer license or equivalent (facilities without one are not eligible); a home-state inspection within the last 18 months; a notarized supervising-pharmacist statement, with a license verification if that pharmacist is not Missouri-licensed; and a $360 fee. The Board's Practice Guide says a licensed Missouri drug outsourcer may supply compounded preparations to providers for office use.

§338.333 was amended by 2026 H.B. 2372 / S.B. 1233, effective 8/28/2026, per the Revisor's history. The specific changes were not itemized here. The current text lets the Board make exceptions by rule for emergencies or supply shortages and allows reciprocity licensing of out-of-state outsourcers. The outsourcer application form is undated. The drug outsourcer category dates to 2018 H.B. 1719.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Missouri is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

RSMo 195.030.2 prohibits anyone from dispensing or prescribing any controlled substance without first obtaining a registration from the Department of Health and Senior Services, and no registration may be granted for more than three years. BNDD's FAQ states that any person in Missouri conducting controlled-substance activities (prescribing, administering, dispensing, stocking) needs a registration, and that a person needs the professional license, then the BNDD registration, then the federal DEA registration. Most practitioners hold one registration at their primary Missouri practice location and may prescribe elsewhere, but a separate registration is required at each location where controlled substances are stocked and stored; a registration terminates if an address change is not reported within 30 days.

Fee and exact cycle were not shown on the pages opened (statute caps the term at 3 years). Applies to mid-level practitioners (APRNs, PAs) with delegated CS authority as well. Per-location: separate registration where controlled substances are stocked.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

RSMo 195.600 (enacted 2021 by S.B. 63) created the statewide PDMP run by the Joint Oversight Task Force for Prescription Drug Monitoring; it requires pharmacies to report Schedule II-IV dispensations and permits prescribers and dispensers to access data, but contains no duty to query. The official Missouri PDMP FAQ states that Missouri law does not mandate providers to check the PDMP before writing or dispensing a prescription, but that the federal SUPPORT Act requires prescribers to check before prescribing a Schedule II, III or IV controlled substance to a MO HealthNet participant. Separately, 9 CSR 30-3.132 requires physicians and staff of certified opioid treatment programs to register with and use a PDMP where available. For a non-Medicaid testosterone patient in an ordinary practice there is no state query mandate.

The FAQ describes the SUPPORT Act requirement as covering Schedule II-IV for MO HealthNet participants; Oregon's Medicaid rule citing the same federal statute (42 U.S.C. 1396w-3a) applies it to Schedule II only, so the scope for Medicaid patients should be confirmed with MO HealthNet. RSMo 195.600 bars interstate data sharing (per FAQ). Statute effective Aug 28, 2021 (source older than 2 years but current per the Revisor site). The PDMP site links rules at 1 CSR 60-1 (not opened).

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

20 CSR 2150-5.020 (Nonpharmacy Dispensing) lets physicians dispense only to patients with whom they have a physician-patient relationship. A physician may not require patients to get drugs only from the office, must generally be present when dispensing occurs (or a PA or collaborative-practice nurse must be), must label drugs with date, patient, directions, physician name and address and drug name and strength, and must keep records. The rule states no registration requirement. Dispensed Schedule II-IV drugs are reportable to Missouri's statewide PDMP (reporting began January 1, 2024 per a vendor summary).

Rule effective January 30, 2010 and still in force at access; source older than 2 years.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

(1) Providers treating patients in Missouri by telehealth must be fully licensed in Missouri; exemptions cover informal or episodic consultation and uncompensated emergency care (RSMo 191.1145). (2) A relationship may be established by a telemedicine encounter if the standard of care does not require in-person care, with an evaluation, history and an exam sufficient for diagnosis; a questionnaire may support the relationship only if it yields in-person-equivalent information, the provider is employed by or contracted with an entity licensed to provide health care in Missouri, and a report goes to the patient's primary care provider within 14 days (RSMo 191.1146, eff. 8/28/2026). (3) As amended by HB 2372, RSMo 334.108.3 prohibits prescribing any drug or controlled substance 'based solely on an evaluation through telemedicine' unless a previously established and ongoing physician-patient relationship exists (the prior text said 'over the telephone'); read literally this reaches Schedule III drugs such as testosterone for new telehealth-only patients, and no Board of Registration for the Healing Arts guidance reconciling it with RSMo 191.1146 was found. (4) IMLC: member.

Least certain entry. HB 2372 (2026, eff. 8/28/2026) changed RSMo 334.108.3 from 'based solely on an evaluation over the telephone' to 'based solely on an evaluation through telemedicine' while the same bill loosened RSMo 191.1146 (physical exam only if the standard of care requires it; questionnaires allowed with conditions). The House bill summary describes the bill as loosening and does not mention the 334.108.3 wording change. How the Board of Registration for the Healing Arts (https://pr.mo.gov/healingarts.asp) will read the two sections together is unknown. Before 8/28/2026 this entry would have been 'yes'.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The Missouri State Board of Nursing's website was checked on 2026-09-23 for a position statement, advisory opinion or FAQ on cosmetic injectables (neuromodulators, fillers) and none was found. RN practice therefore falls under the state's general nurse practice act, which was not reviewed for this entry.

The Board's position-statement page (pr.mo.gov/nursing-focus-position.asp) lists no aesthetics statement.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The Missouri State Board of Nursing's website was checked on 2026-09-23 for guidance on IV hydration clinics (prior exams, standing orders, mobile services) and none was found.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide lists Missouri as permitted, citing State ex rel. Sager v. Lewin (Mo. Ct. App. 1907) and a 1962 Attorney General opinion; MedPath Compliance (reviewed 2026-06-20) also lists Missouri as 'No'.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

No Missouri statute, rule or board policy on delegation of cosmetic laser/IPL procedures or a laser-operator credential was located on 2026-09-23.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Missouri was not among them, but this research did not confirm its statutes. Missouri's CLIA state agency is Missouri DHSS, Bureau of Diagnostic Services, CLIA Laboratory Program (CLIA@health.mo.gov, 573-751-6318); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Missouri's rule. Missouri's lab regulator (CLIA state agency) is Missouri DHSS, Bureau of Diagnostic Services, CLIA Laboratory Program (CLIA@health.mo.gov, 573-751-6318). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Missouri is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Missouri does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.